Spectral MD Holdings

Spectral AI is a predictive analytics company specializing in medical diagnostics through the use of artificial intelligence and multispectral imaging. The company's core technology, the DeepView AI platform, is designed to provide clinicians with an objective, immediate assessment of a wound's healing potential. Currently, the company focuses on two primary applications: burn wound depth assessment and diabetic foot ulcer (DFU) healing prediction. By distinguishing between healing and non-healing tissue at an early stage, Spectral AI aims to optimize treatment plans, reduce unnecessary surgeries, and improve patient outcomes. The company is heavily supported by the U.S. government through significant contracts with BARDA and is currently conducting pivotal clinical trials for its burn indication.